Waltham, MA, United States
Waltham, MA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
ImmunoGen | Date: 2017-07-26

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.


The present invention provides improved methods for formulating therapeutic compositions comprising an antibody drug conjugate (ADC) that reduce potency variability between batches of ADC and provide for administration of such therapeutic compositions within a narrow intended range. The current invention provides a novel method for formulating a therapeutic composition comprising an antibody drug conjugate (ADC) based on drug concentration, thereby narrowing variability in potency between batches of ADC, minimizing toxicity and increasing the efficacy of drug formulated according to this method.


Patent
ImmunoGen | Date: 2017-07-12

The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)- (VI). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.


The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.


Patent
ImmunoGen | Date: 2017-07-12

The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.


The invention features methods for characterizing and treating acute myeloid leukemia (AML) (e.g., newly diagnosed, relapsed, and refractory AML) in a subject using immunoconjugates of the invention. In one aspect, the invention generally features a method of treating acute myeloid leukemia in a subject (e.g., a human), the method involving administering an effective amount of an immunoconjugate to a pre-selected subject, where the immunoconjugate contains a humanized or chimeric antibody or fragment conjugated to a cytotoxic benzodiazepine dimer compound via a cleavable disulfide linker.


Patent
ImmunoGen | Date: 2016-07-21

The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.


Patent
ImmunoGen | Date: 2016-07-21

The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.


Patent
ImmunoGen | Date: 2016-07-21

The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.


Patent
ImmunoGen | Date: 2017-04-12

Processes for the preparation of charged crosslinkers bearing a sulfonic acid moiety are disclosed. These procedures also optionally include methods to convert the resulting products to substantially a single salt form.

Loading ImmunoGen collaborators
Loading ImmunoGen collaborators